Novogen Appoints Three New Directors
September 20, 2010 08:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - September 20, 2010) - Pharmaceutical development company, Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has appointed three new Directors.
Of the three...
Novogen Restructures Australian Management Team and Marshall Edwards Appoints CFO
June 18, 2010 09:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
June 17, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol
June 01, 2010 08:31 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Marshall Edwards Appoints New President and CEO
April 26, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
Novogen Announces New Executive Service Agreements
March 31, 2010 08:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - March 31, 2010) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) advises that it has entered into new executive service agreements with its seven most senior executives.
...
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
March 31, 2010 08:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
February 08, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Christopher Naughton had resigned as a member of the Board
of Directors effective February 5,...
Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
April 20, 2009 08:00 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 20, 2009) - Data presented
yesterday at the Annual Meeting of the American Association for Cancer
Research in Denver has demonstrated that...
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
April 14, 2009 08:20 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an
un-blinded analysis of the data from its...